Exploration of Targeted Anti-tumor Therapy

Table 4. Characteristics and outcomes of TRT studies in SCLC and NSCLC.

Study (first author, year)	Sample size	Therapeutic agent	Number of cycles	Response criteria	Response rate (PR+SD)	Median PFS (months)	Median OS (months)	Major toxicity
Xie, 2024, [23]	9	[¹⁷⁷Lu]Lu-FAP-2286	Mean 3.1 (2–6)	RECIST 1.1	44.4%	6	10	Mild (no grade III/IV)
Yu, 2006, [27]	43	[¹³¹I]Iodine-chTNT	2	WHO	9.1%	Not reported	Not reported	Mild to moderate hematologic toxicity

Return to article view

NSCLC: non-small cell lung cancer; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease; RECIST 1.1: Response Evaluation Criteria in Solid Tumors Version 1.1; SCLC: small cell lung cancer; TRT: targeted radioligand therapy; WHO: World Health Organization.

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1002368_sup_1.pdf.

Declarations

Author contributions

SM and SR: Conceptualization, Data curation, Formal analysis, Writing—original draft. KAR, MJAJ, and MA: Writing—review & editing, Visualization. AA, NA, and UAR: Data curation, Formal analysis. AAI: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable. This systematic review synthesizes data from previously published studies and does not involve human participants or animal subjects.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in the manuscript.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. [DOI] [PubMed]

Inamura K. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017;7:193. [DOI] [PubMed] [PMC]

Blackhall F, Girard N, Livartowski A, McDonald L, Roset M, Lara N, et al. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study. BMJ Open. 2023;13:e052556. [DOI] [PubMed] [PMC]

Liang B, Tong C, Nong J, Zhang Y. Histological Subtype Classification of Non-Small Cell Lung Cancer with Radiomics and 3D Convolutional Neural Networks. J Imaging Inform Med. 2024;37:2895–909. [DOI] [PubMed] [PMC]

Jeon H, Wang S, Song J, Gill H, Cheng H. Update 2025: Management of NonSmall-Cell Lung Cancer. Lung. 2025;203:53. [DOI] [PubMed] [PMC]

Niho S. Treatment of small cell lung cancer; advances and future prospects. Respir Investig. 2025;63:680–5. [DOI] [PubMed]

Al-Ibraheem A, Zimmermann R, Abdlkadir AS, Herrmann K. Radiotheranostics Global Market and Future Developments. Semin Nucl Med. 2024;54:622–33. [DOI] [PubMed]

Al-Ibraheem A, Brink A, Lee ST, De Los Reyes A, Paez D, Craviolatti PS, et al. Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access. Semin Nucl Med. 2025;55:1032–44. [DOI] [PubMed]

Watabe T, Hirata K, Iima M, Yanagawa M, Saida T, Sakata A, et al. Recent advances in theranostics and oncology PET: emerging radionuclides and targets. Ann Nucl Med. 2025;39:909–21. [DOI] [PubMed] [PMC]

10.

Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, et al. Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative. J Nucl Med. 2025;66:757–63. [DOI] [PubMed]

11.

Abdlkadir AS, Al-Adhami D, Al-Rasheed U, Jreige M, Mahafza W, Al-Khawaldeh K, et al. PET imaging and radionuclide therapy in neuroendocrine prostate cancer: a systematic review. Q J Nucl Med Mol Imaging. 2025;69:99–117. [DOI] [PubMed]

12.

Al-Ibraheem A, Abdlkadir AS, Sweedat DA, Maus S, Al-Rasheed U, Salah S, et al. From Despair to Hope: First Arabic Experience of ¹⁷⁷Lu-PSMA and ¹⁶¹Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2024;16:1974. [DOI] [PubMed] [PMC]

13.

Naraev BG, Ramirez RA, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids. Clin Lung Cancer. 2019;20:e376–92. [DOI] [PubMed]

14.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. [DOI] [PubMed] [PMC]

15.

Calderon Martinez E, Ghattas Hasbun PE, Salolin Vargas VP, García-González OY, Fermin Madera MD, Rueda Capistrán DE, et al. A comprehensive guide to conduct a systematic review and meta-analysis in medical research. Medicine (Baltimore). 2025;104:e41868. [DOI] [PubMed] [PMC]

16.

Selçuk AA. A Guide for Systematic Reviews: PRISMA. Turk Arch Otorhinolaryngol. 2019;57:57–8. [DOI] [PubMed] [PMC]

17.

Saad Ruzzeh, Serin Moghrabi. The Evolving Role of Targeted Radioligand Therapy in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review. PROSPERO 2025 CRD420251238530 [Internet]. NIHR; c2025 [cited 2025 Nov 25]. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251238530

18.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. [DOI] [PubMed] [PMC]

19.

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–7. [DOI] [PubMed] [PMC]

20.

O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology. 2016;280:576–84. [DOI] [PubMed] [PMC]

21.

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112:90–2. Spanish. [DOI] [PubMed]

22.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. [DOI] [PubMed] [PMC]

23.

Xie Y, Ma J, Tang W, Zhang Y, Zhang C, Chen Y. Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer. Clin Nucl Med. 2024;49:830–7. [DOI] [PubMed]

24.

Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study. Clin Nucl Med. 2021;46:e523–30. [DOI] [PubMed]

25.

Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. Lung Cancer. 2004;45:365–71. [DOI] [PubMed]

26.

Sollini M, Farioli D, Froio A, Chella A, Asti M, Boni R, et al. Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients. J Thorac Oncol. 2013;8:1095–101. [DOI] [PubMed]

27.

Yu L, Ju DW, Chen W, Li T, Xu Z, Jiang C, et al. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006;21:5–14. [DOI] [PubMed]

28.

Liu H, Guo R, Zhang X, Ji H, Sun S, Sun S, et al. Safety and efficacy of ¹⁷⁷Lu-FAPI-XT radioligand therapy in patients with advanced sarcoma and other cancer entities: first-in-human, dose-escalation study. Eur J Nucl Med Mol Imaging. 2026;53:1869–80. [DOI] [PubMed] [PMC]

29.

Fu H, Huang J, Zhao L, Chen Y, Xu W, Cai J, et al. 177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study. Clin Cancer Res. 2025;31:1415–26. [DOI] [PubMed] [PMC]

30.

Serfling SE, Hartrampf PE, Zhi Y, Higuchi T, Kosmala A, Serfling J, et al. Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer. Clin Nucl Med. 2023;48:309–14. [DOI] [PubMed] [PMC]

31.

Lapa C, Hänscheid H, Wild V, Pelzer T, Schirbel A, Werner RA, et al. Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy. Oncotarget. 2016;7:20033–40. [DOI] [PubMed] [PMC]

32.

Şen F, Sheikh GT, von Hinten J, Schindele A, Kircher M, Dierks A, et al. In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target. Cancers (Basel). 2023;15:3595. [DOI] [PubMed] [PMC]

33.

Aggarwal P, Anwariya A, Kaur K, Satapathy S, Sood A, Singh N, et al. PSMA-based Theranostics in Advanced Non-small Cell Lung Cancer: A Hit or a Miss? Clin Nucl Med. 2026;51:e120–2. [DOI] [PubMed]

34.

Rao Z, Zhang Y, Liu L, Wang M, Zhang C. [¹⁷⁷Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases. Eur J Nucl Med Mol Imaging. 2023;50:1266–7. [DOI] [PubMed]

35.

Yang H, Liu H, Zhang Y, Zhang Y, Chen Y. Metastatic Lung Adenocarcinoma Received Combined 177 Lu-FAP-2286 Radiation Therapy and Targeted Therapy. Clin Nucl Med. 2024;49:569–71. [DOI] [PubMed]

36.

Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S. Significant response to [²²⁵Ac]Ac-DOTATATE therapy in a patient with small cell lung cancer. Eur J Nucl Med Mol Imaging. 2025;52:2743–4. [DOI] [PubMed]

37.

van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599–606. [PubMed]

38.

Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O, et al. Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review. Nucl Med Mol Imaging. 2025;59:50–61. [DOI] [PubMed] [PMC]

39.

Verwer EE, Zegers CML, van Elmpt W, Wierts R, Windhorst AD, Mottaghy FM, et al. Pharmacokinetic modeling of a novel hypoxia PET tracer [¹⁸F]HX4 in patients with non-small cell lung cancer. EJNMMI Phys. 2016;3:30. [DOI] [PubMed] [PMC]

40.

Urso L, Napolitano R, Speltri G, Tuncel M, Badrane I, Uccelli L, et al. ⁶⁸Ga-Trivehexin: Current Status of αvβ6-Integrin Imaging and Perspectives. Cancers (Basel). 2025;17:1504. [DOI] [PubMed] [PMC]

41.

Ruigrok EAM, Verhoeven M, Konijnenberg MW, de Blois E, de Ridder CMA, Stuurman DC, et al. Safety of [¹⁷⁷Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging. 2022;49:4440–51. [DOI] [PubMed] [PMC]